Nkechinyere Nwamaka Ijioma, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiology | 8 | 2023 | 1668 | 0.940 |
Why?
|
| Azetidines | 1 | 2011 | 142 | 0.350 |
Why?
|
| Simvastatin | 1 | 2011 | 360 | 0.320 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 604 | 0.280 |
Why?
|
| Coronary Vessels | 3 | 2023 | 3107 | 0.270 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 789 | 0.270 |
Why?
|
| Internship and Residency | 1 | 2021 | 5791 | 0.200 |
Why?
|
| Accreditation | 1 | 2021 | 452 | 0.160 |
Why?
|
| Education, Medical, Graduate | 3 | 2021 | 2291 | 0.150 |
Why?
|
| Women's Health | 3 | 2022 | 2034 | 0.150 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2015 | 49 | 0.130 |
Why?
|
| Cardiovascular System | 1 | 2022 | 831 | 0.120 |
Why?
|
| American Heart Association | 3 | 2023 | 1057 | 0.120 |
Why?
|
| Myocardial Contraction | 1 | 2019 | 1579 | 0.120 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 1607 | 0.110 |
Why?
|
| Postmenopause | 1 | 2022 | 2460 | 0.110 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2015 | 493 | 0.110 |
Why?
|
| Electric Countershock | 1 | 2015 | 534 | 0.100 |
Why?
|
| Coronary Stenosis | 1 | 2018 | 834 | 0.100 |
Why?
|
| Clinical Competence | 3 | 2021 | 4687 | 0.090 |
Why?
|
| Angiography | 1 | 2015 | 1639 | 0.090 |
Why?
|
| Heart Ventricles | 2 | 2019 | 3817 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2021 | 2789 | 0.080 |
Why?
|
| United States | 8 | 2023 | 69872 | 0.080 |
Why?
|
| Stroke Volume | 1 | 2019 | 5006 | 0.070 |
Why?
|
| Heart Failure | 2 | 2022 | 10895 | 0.070 |
Why?
|
| Electrocardiography | 2 | 2018 | 6442 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2011 | 1958 | 0.070 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2010 | 582 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2018 | 10252 | 0.060 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 4583 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2021 | 63107 | 0.060 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 2337 | 0.060 |
Why?
|
| Anticholesteremic Agents | 1 | 2011 | 979 | 0.060 |
Why?
|
| Docosahexaenoic Acids | 1 | 2010 | 875 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 2 | 2023 | 1831 | 0.050 |
Why?
|
| Registries | 1 | 2018 | 8091 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2015 | 2758 | 0.050 |
Why?
|
| HIV-1 | 1 | 2019 | 6939 | 0.050 |
Why?
|
| Humans | 17 | 2023 | 744366 | 0.040 |
Why?
|
| Radial Artery | 1 | 2021 | 194 | 0.040 |
Why?
|
| Social Isolation | 1 | 2022 | 365 | 0.040 |
Why?
|
| Research Report | 1 | 2022 | 355 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2023 | 3743 | 0.040 |
Why?
|
| Femoral Artery | 1 | 2021 | 845 | 0.040 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 3154 | 0.030 |
Why?
|
| Echocardiography | 2 | 2019 | 5099 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3255 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2010 | 4043 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 15160 | 0.030 |
Why?
|
| Credentialing | 1 | 2015 | 126 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 11718 | 0.030 |
Why?
|
| HIV Infections | 1 | 2019 | 16715 | 0.030 |
Why?
|
| Risk Factors | 4 | 2022 | 72296 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 1771 | 0.030 |
Why?
|
| Cognition | 1 | 2010 | 6770 | 0.030 |
Why?
|
| Incidence | 2 | 2022 | 20952 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2015 | 1851 | 0.020 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 1066 | 0.020 |
Why?
|
| Health Policy | 1 | 2022 | 2661 | 0.020 |
Why?
|
| Aged | 5 | 2022 | 163288 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2021 | 1796 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2021 | 3461 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 39052 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 3666 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 1078 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2018 | 4576 | 0.020 |
Why?
|
| Forecasting | 1 | 2015 | 2951 | 0.020 |
Why?
|
| Female | 6 | 2022 | 380193 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2015 | 1354 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2018 | 5316 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 12356 | 0.010 |
Why?
|
| Prevalence | 1 | 2019 | 15221 | 0.010 |
Why?
|
| Hospitalization | 1 | 2022 | 10259 | 0.010 |
Why?
|
| Curriculum | 1 | 2015 | 3605 | 0.010 |
Why?
|
| Animals | 2 | 2011 | 168768 | 0.010 |
Why?
|
| Pandemics | 1 | 2022 | 8385 | 0.010 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2010 | 1344 | 0.010 |
Why?
|
| Time Factors | 1 | 2018 | 40075 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 57776 | 0.010 |
Why?
|
| Dementia | 1 | 2010 | 2518 | 0.010 |
Why?
|
| Male | 3 | 2019 | 350115 | 0.010 |
Why?
|
| Middle Aged | 2 | 2019 | 213390 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2018 | 53290 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 24252 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 9955 | 0.010 |
Why?
|
| Aging | 1 | 2010 | 8664 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 77460 | 0.010 |
Why?
|
| Adult | 1 | 2019 | 214052 | 0.000 |
Why?
|